Cargando…

Dl-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling

INTRODUCTION: Lung cancer serves as one of the most malignant cancer types. Immunotherapy targeting PD-1/PD-L1 axis is a promising strategy for cancer treatment. Dl-3-N-butylphthalide (NBP), a small molecule compound extracted from the seeds of Apium graveolens, possesses a large range of biological...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Qian, Zhang, Nan, Li, Xin, Hou, Wei, Zhao, Xiao-Qing, Liu, Lei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8594621/ https://www.ncbi.nlm.nih.gov/pubmed/34795530 http://dx.doi.org/10.2147/CMAR.S333416

Ejemplares similares

Dl-3-n-Butylphthalide Exerts Dopaminergic Neuroprotection Through Inhibition of Neuroinflammation
por: Chen, Yajing, et al.
Publicado: (2019)

Corrigendum: Dl-3-n-Butylphthalide Exerts Dopaminergic Neuroprotection Through Inhibition of Neuroinflammation
por: Chen, Yajing, et al.
Publicado: (2021)

Protective effects of dl-3n-butylphthalide against diffuse brain injury
por: Zhao, Yaning, et al.
Publicado: (2013)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Dl-3-n-Butylphthalide Ameliorates Diabetic Nephropathy by Ameliorating Excessive Fibrosis and Podocyte Apoptosis
por: Xu, Jingyu, et al.
Publicado: (2021)

Dl-3-n-butylphthalide regulates cholinergic dysfunction in chronic cerebral hypoperfusion rats
por: Sun, Yanan, et al.
Publicado: (2020)

Dl-3-n-butylphthalide Reduces Neurovascular Inflammation and Ischemic Brain Injury in Mice
por: Yang, Chun-Sheng, et al.
Publicado: (2019)

Effects of Dl-3-n-butylphthalide on Cerebral Ischemia Infarction in Rat Model by Mass Spectrometry Imaging
por: Liu, Run-Zhe, et al.
Publicado: (2017)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
por: Banna, Giuseppe Luigi, et al.
Publicado: (2020)

Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer
por: de Jong, Florus C., et al.
Publicado: (2021)

DL-3-n-butylphthalide alleviates motor disturbance by suppressing ferroptosis in a rat model of Parkinson’s disease
por: Hu, Chun-Bo, et al.
Publicado: (2022)

Protective Effect of Dl-3n-butylphthalide on Learning and Memory Impairment Induced by Chronic Intermittent Hypoxia-Hypercapnia Exposure
por: Min, Jing-jing, et al.
Publicado: (2014)

Effect of Dl-3-n-butylphthalide on mitochondrial Cox7c in models of cerebral ischemia/reperfusion injury
por: Jia, Jingjing, et al.
Publicado: (2023)

The efficacy and safety of Dl-3n-butylphthalide on progressive cerebral infarction: A randomized controlled STROBE study
por: Zhang, Chenhao, et al.
Publicado: (2017)

Dl-3-n-butylphthalide inhibits neuroinflammation by stimulating foxp3 and Ki-67 in an ischemic stroke model
por: Liu, Xi, et al.
Publicado: (2021)

Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
por: Su, Chaoyue, et al.
Publicado: (2020)

Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer
por: Wang, Luyao, et al.
Publicado: (2023)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer
por: Jiang, Siqing, et al.
Publicado: (2022)

Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao, María, et al.
Publicado: (2015)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
por: Botticelli, Andrea, et al.
Publicado: (2021)

A novel [(89)Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer
por: Puyalto, Ander, et al.
Publicado: (2023)

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
por: Cheng, Chao, et al.
Publicado: (2022)

Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis
por: Liu, Junqi, et al.
Publicado: (2018)

Dl-3-n-Butylphthalide promotes neovascularization and neurological recovery in a rat model of intracerebral hemorrhage
por: Tu, Ewen, et al.
Publicado: (2020)

DL-3-n-butylphthalide Increases Collateriogenesis and Functional Recovery after Focal Ischemic Stroke in Mice
por: Wei, Zheng Zachory, et al.
Publicado: (2021)

Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers
por: Pei, Liping, et al.
Publicado: (2023)

PD-L1 degradation pathway and immunotherapy for cancer
por: Gou, Qian, et al.
Publicado: (2020)

Dl-NBP (Dl-3-N-Butylphthalide) Treatment Promotes Neurological Functional Recovery Accompanied by the Upregulation of White Matter Integrity and HIF-1α/VEGF/Notch/Dll4 Expression
por: Wang, Yanping, et al.
Publicado: (2020)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer
por: Qiao, Xin-wei, et al.
Publicado: (2020)

The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis
por: Chen, Xiao-Jiang, et al.
Publicado: (2020)

Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry
por: Kwiecień, Iwona, et al.
Publicado: (2021)

A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer
por: You, Wei, et al.
Publicado: (2018)

Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer
por: Shah, Shalin, et al.
Publicado: (2017)

Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
por: Nishioka, Naoya, et al.
Publicado: (2019)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
por: Yang, Bo, et al.
Publicado: (2018)

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
por: Sato, Hiro, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7qqhkhcb6q6su2ru3le9mkl122